London, UK – 5 November 2025 – Touchlight, a leader in cell-free DNA technology, today announced the expansion of its groundbreaking mbDNA™ platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA. These innovative constructs join mbDNA, which debuted earlier this year, to form a comprehensive portfolio designed to overcome the limitations of traditional gene editing tools. 

The mbDNA platform and new custom circle DNA architectures deliver enhanced stability, reduced immunogenicity, and compatibility with a broad range of gene insertion and expression technologies, setting a new standard for precision and performance in genetic engineering. 

mbDNA (megabulb DNA) is a pioneering single-stranded DNA technology produced through Touchlight’s cell-free enzymatic platform, delivering high purity and minimal immunogenicity for safer outcomes plus enzymatic production for optimal reliability and scalability. It achieves high HDR efficiency with low toxicity, consistently reaching knock-in rates of 60–75% in primary T cells, while offering predictable performance with low donor-donor variability. Additionally, mbDNA supports expanded payload capacity of up to 20kb, enabling the delivery of large genetic cargos and unlocking new possibilities for advanced gene editing. 

Applications include homology-directed repair (HDR), and episomal expression. 

Introducing sscDNA, hsscDNA, and dscDNA 

The flexible nature of Touchlight’s novel circular DNA molecules allows for bespoke designs to optimize gene therapy platforms that utilize DNA payloads for episomal expression or integration.  sscDNA is a fully single-stranded circular DNA molecule, whereas hsscDNA contains bespoke double stranded region(s) of user-defined length.  dscDNA is a fully double stranded circular molecule. The sequence of all DNA constructs are completely user defined and ideal for transposases, recombinases, HITI, and episomal expression.  

 “mbDNA is a market leading technology providing the best-in-class HDR template available today,” said Karen Fallen, CEO at Touchlight. “With the addition of sscDNA, hsscDNA, and dscDNA, we’re empowering researchers and developers to unlock new possibilities in gene editing and therapeutic innovation.” 

About Touchlight

Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers, with an FDA Drug Master File accepted in 2022 followed in 2025 with the world’s first cell-free DNA GMP license, Touchlight’s enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing technology with its state-of-the-art facility recognised by ISPE’s Facility of the Year Awards (FOYA) for Innovation.

With multiple client products already in the clinic, Touchlight’s evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognising the urgent need for innovative DNA production techniques to support the future of genetic therapies.

For more information please contact:

Karen Fallen, Chief Executive Officer
Verna McErlane, Chief Commercial Officer
E: info@touchlight.com
T: +44 20 8481 9200